{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:24:05Z","timestamp":1791606245164,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1208\/s12248-021-00601-0","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T18:02:56Z","timestamp":1623952976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Use of Physiologically Based Pharmacokinetic Modeling for Predicting Drug\u2013Food Interactions: Recommendations for Improving Predictive Performance of Low Confidence Food Effect Models"],"prefix":"10.1208","volume":"23","author":[{"given":"Christian","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippos","family":"Kesisoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier J. H.","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Parrott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Emami Riedmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"issue":"3","key":"601_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00003088-199936030-00004","volume":"36","author":"D Fleisher","year":"1999","unstructured":"Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36(3):233\u201354.","journal-title":"Clin Pharmacokinet"},{"key":"601_CR2","unstructured":"FDA. Assessing the effects of food on drugs in INDs and NDAs \u2014 clinical pharmacology considerations guidance for industry. 2019. https:\/\/www.fda.gov\/media\/121313\/download"},{"issue":"2","key":"601_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/psp4.12260","volume":"7","author":"M Li","year":"2018","unstructured":"Li M, Zhao P, Pan Y, Wagner C. Predictive performance of physiologically based pharmacokinetic models for the effect of food on oral drug absorption: current status. CPT Pharmacometrics Syst Pharmacol. 2018;7(2):82\u20139.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"123","key":"601_CR4","first-page":"1","volume":"22","author":"A Emami Riedmaier","year":"2020","unstructured":"Emami Riedmaier A, DeMent K, Huckle J, Bransford P, Stillhart C, Alluri R, et al. Use of PBPK modeling for predicting drug-food interactions: an industry perspective. AAPS J. 2020;22(123):1\u201315.","journal-title":"AAPS J"},{"key":"601_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1208\/s12248-020-00548-8","volume":"23","author":"X Pepin","year":"2021","unstructured":"Pepin X, Huckle JE, Alluri RV, Basu S, Dodd S, Parrott N, et al. Understanding mechanisms of food effect and developing reliable PBPK models using a middle-out approach. AAPS J. 2021;23:12.","journal-title":"AAPS J"},{"issue":"5","key":"601_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/00498254.2012.734642","volume":"43","author":"Y Deng","year":"2013","unstructured":"Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, et al. Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013;43(5):443\u201353.","journal-title":"Xenobiotica."},{"issue":"12","key":"601_CR7","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220\u20137.","journal-title":"Clin Cancer Res"},{"key":"601_CR8","unstructured":"FDA. Clinical Pharmacology and Biopharmaceutics review for Votrient (NDA 22-465). 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_clinpharmr.pdf"},{"issue":"6","key":"601_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/clpt.2010.199","volume":"88","author":"EI Heath","year":"2010","unstructured":"Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(6):818\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"601_CR10","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1021\/acs.molpharmaceut.9b00534","volume":"16","author":"C Jede","year":"2019","unstructured":"Jede C, Wagner C, Kubas H, Weigandt M, Weber C, Lecomte M, et al. Improved prediction of in vivo supersaturation and precipitation of poorly soluble weakly basic drugs using a biorelevant bicarbonate buffer in a gastrointestinal transfer model. Mol Pharm. 2019;16(9):3938\u201347.","journal-title":"Mol Pharm"},{"issue":"5","key":"601_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2036.1994.tb00319.x","volume":"8","author":"DL Hogan","year":"1994","unstructured":"Hogan DL, Ainsworth MA, Isenberg JI. Review article: gastroduodenal bicarbonate secretion. Aliment Pharmacol Ther. 1994;8(5):475\u201388.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"601_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","volume":"44","author":"O Doroshyenko","year":"2005","unstructured":"Doroshyenko O, Jetter A, Odenthal K, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701\u201320.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"601_CR13","first-page":"984","volume":"36","author":"G Schladitz-Keil","year":"1986","unstructured":"Schladitz-Keil G, Spahn H, Mutschler E. Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. Arzneimittel-Forschung. 1986;36(6):984\u20137.","journal-title":"Arzneimittel-Forschung."},{"key":"601_CR14","unstructured":"FDA. Clinical Pharmacology and Biopharmaceutics review for Sanctura (NDA 21-595). 2004. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-595_Sanctura_BioPharmr_P1.pdf"},{"key":"601_CR15","unstructured":"FDA. Clinical Pharmacology and Biopharmaceutics review for Sanctura XR (NDA 22-103). 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022103s000_ClinPharmR.pdf"},{"issue":"11","key":"601_CR16","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1021\/mp400179v","volume":"10","author":"CA Heinen","year":"2013","unstructured":"Heinen CA, Reuss S, Amidon GL, Langguth P. Ion pairing with bile salts modulates intestinal permeability and contributes to food\u2013drug interaction of BCS class III compound trospium chloride. Mol Pharm. 2013;10(11):3989\u201396.","journal-title":"Mol Pharm"},{"issue":"1-2","key":"601_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijpharm.2016.10.030","volume":"515","author":"T Tadken","year":"2016","unstructured":"Tadken T, Weiss M, Modess C, Wegner D, Roustom T, Neumeister C, et al. Trospium chloride is absorbed from two intestinal \u201cabsorption windows\u201d with different permeability in healthy subjects. Int J Pharm. 2016;515(1-2):367\u201373.","journal-title":"Int J Pharm"},{"issue":"7","key":"601_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/bdd.1798","volume":"33","author":"A Radwan","year":"2012","unstructured":"Radwan A, Amidon GL, Langguth P. Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity: mechanism of food effect for BCS class III product. Biopharm Drug Dispos. 2012;33(7):403\u201316.","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"601_CR19","first-page":"58","volume":"40","author":"JJ Miceli","year":"2007","unstructured":"Miceli JJ, Glue P, Alderman J, Wilner K. The effect of food on the absorption of oral ziprasidone. Psychopharmacol Bull. 2007;40(3):58\u201368.","journal-title":"Psychopharmacol Bull"},{"key":"601_CR20","unstructured":"FDA. Clinical Pharmacology and Biopharmaceutics review for Geodon (NDA 20-825). 2004. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/20-825_Geodan.cfm"},{"key":"601_CR21","unstructured":"FDA. Approved label for Geodon. 2008. p. Revised June 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020825s035,020919s023lbl.pdf"},{"issue":"6","key":"601_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1023\/A:1012102522787","volume":"14","author":"S Yee","year":"1997","unstructured":"Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man\u2014fact or myth. Pharm Res. 1997;14(6):763\u20136.","journal-title":"Pharm Res"},{"issue":"4","key":"601_CR23","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1208\/s12248-017-0065-9","volume":"19","author":"S Sutton","year":"2017","unstructured":"Sutton S, Nause R, Gandelman K. The impact of gastric pH, volume, and emptying on the food effect of ziprasidone oral absorption. AAPS J. 2017;19(4):1084\u201390.","journal-title":"AAPS J"},{"key":"601_CR24","unstructured":"GSK. An open-label, two-period, randomized, crossover study to evaluate the effect of food on the pharmacokinetics of single doses of pazopanib in cancer subjects (food-effect results only) In: Register G-CS, editor. 2007. https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/VEG10005\/3ac4a918-ecb5-4e42-90e9-aaf01a451734\/05e47103-37ae-4f2e-a3d1-c3f17953e1f1\/gsk-veg10005-clinical-study-report-redact-v1.pdf"},{"issue":"05","key":"601_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0032-1304649","volume":"62","author":"R Zhang","year":"2012","unstructured":"Zhang R, Yuan G, Li R, Liu X, Wei C, Wang B, et al. Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. Arzneimittelforschung. 2012;62(05):247\u201351.","journal-title":"Arzneimittelforschung."},{"issue":"1","key":"601_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4088\/JCP.08m04104","volume":"70","author":"K Gandelman","year":"2009","unstructured":"Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58\u201362.","journal-title":"J Clin Psychiatry"},{"key":"601_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00487-5","volume":"25","author":"D H\u00f6rter","year":"1997","unstructured":"H\u00f6rter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 1997;25:3\u201314.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"601_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0016-5085(76)80010-8","volume":"70","author":"JR Malagelada","year":"1976","unstructured":"Malagelada JR, Longstreth GF, Summerskill WH, Go VL. Measurement of gastric functions during digestion of ordinary solid meals in man. Gastroenterology. 1976;70(2):203\u201310.","journal-title":"Gastroenterology"},{"issue":"Pt A","key":"601_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2015.10.022","volume":"220","author":"M Koziolek","year":"2015","unstructured":"Koziolek M, Schneider F, Grimm M, Modebeta C, Seekamp A, Roustom T, et al. Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies. J Control Release. 2015;220(Pt A):71\u20138.","journal-title":"J Control Release"},{"issue":"10","key":"601_CR30","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/jcph.1421","volume":"59","author":"T Abebe Bayew","year":"2019","unstructured":"Abebe Bayew T, Weiss M, Modess C, Roustom T, Tadken T, Wegner D, et al. Effects of the P-glycoprotein inhibitor clarithromycin on the pharmacokinetics of intravenous and oral trospium chloride: a 4-way crossover drug-drug interaction study in healthy subjects. J Clin Pharmacol. 2019;59(10):1319\u201330.","journal-title":"J Clin Pharmacol"},{"key":"601_CR31","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.ejps.2020.105543","volume":"155","author":"Y Akiyama","year":"2020","unstructured":"Akiyama Y, Ito S, Fujita T, Sugano K. Prediction of negative food effect induced by bile micelle binding on oral absorption of hydrophilic cationic drugs. Eur J Pharm Sci. 2020;155:105543.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"601_CR32","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/mp200181v","volume":"8","author":"JM Miller","year":"2011","unstructured":"Miller JM, Beig A, Krieg BJ, Carr RA, Borchardt TB, Amidon GE, et al. The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm. 2011;8(5):1848\u201356.","journal-title":"Mol Pharm"},{"issue":"1-2","key":"601_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ijpharm.2008.10.001","volume":"368","author":"K Sugano","year":"2009","unstructured":"Sugano K. Estimation of effective intestinal membrane permeability considering bile micelle solubilisation. Int J Pharm. 2009;368(1-2):116\u201322.","journal-title":"Int J Pharm"},{"issue":"11","key":"601_CR34","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1111\/j.2042-7158.2010.01023.x","volume":"62","author":"K Kleberg","year":"2010","unstructured":"Kleberg K, Jacobsen J, Mullertz A. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol. 2010;62(11):1656\u201368.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"601_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0378-5173(94)90142-2","volume":"109","author":"JR O'Reilly","year":"1994","unstructured":"O'Reilly JR, Corrigan OI, O'Driscoll CM. The effect of mixed micellar systems, bile salt\/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anaesthetised rat. Int J Pharm. 1994;109(2):147\u201354.","journal-title":"Int J Pharm"},{"issue":"2","key":"601_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2008.09.008","volume":"61","author":"RA Cone","year":"2009","unstructured":"Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75\u201385.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"601_CR37","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.bbalip.2010.05.014","volume":"1801","author":"R Ehehalt","year":"2010","unstructured":"Ehehalt R, Braun A, Karner M, F\u00fcllekrug J, Stremmel W. Phosphatidylcholine as a constituent in the colonic mucosal barrier-physiological and clinical relevance. Biochim Biophys Acta. 2010;1801(9):983\u201393.","journal-title":"Biochim Biophys Acta"},{"issue":"Suppl 1","key":"601_CR38","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0169-409X(01)00181-8","volume":"50","author":"H Shen","year":"2001","unstructured":"Shen H, Howles P, Tso P. From interaction of lipidic vehicles with intestinal epithelial cell membranes to the formation and secretion of chylomicrons. Adv Drug Deliv Rev. 2001;50(Suppl 1):S103\u201325.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"601_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/js960085v","volume":"86","author":"WN Charman","year":"1997","unstructured":"Charman WN, Porter CJH, Mithani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86(3):269\u201382.","journal-title":"J Pharm Sci"},{"issue":"1-2","key":"601_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpharm.2006.08.043","volume":"330","author":"H Lin","year":"2007","unstructured":"Lin H, Gebhardt M, Bian S, Kwon KA, Shim CK, Chung SJ, et al. Enhancing effect of surfactants on fexofenadine.HCl transport across the human nasal epithelial cell monolayer. Int J Pharm. 2007;330(1-2):23\u201331.","journal-title":"Int J Pharm"},{"issue":"6","key":"601_CR41","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1172\/JCI106931","volume":"51","author":"ER Schiff","year":"1972","unstructured":"Schiff ER, Small NC, Dietschy JM. Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Investig. 1972;51(6):1351\u201362.","journal-title":"J Clin Investig"},{"key":"601_CR42","unstructured":"Arenson DR, Qi H, inventors; Pfizer Inc., assignee. Ziprasidone suspension. USA patent US 7,175,855 B1 2007 13\/02\/07."},{"issue":"6","key":"601_CR43","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/0091270005276485","volume":"45","author":"JJ Miceli","year":"2005","unstructured":"Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. J Clin Pharmacol. 2005;45(6):620\u201330.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"601_CR44","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1111\/j.1750-3841.2010.01748.x","volume":"75","author":"MJ Ferrua","year":"2010","unstructured":"Ferrua MJ, Singh RP. Modeling the fluid dynamics in a human stomach to gain insight of food digestion. J Food Sci. 2010;75(7):R151\u201362.","journal-title":"J Food Sci"},{"key":"601_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2016.03.009","volume":"101","author":"M Koziolek","year":"2016","unstructured":"Koziolek M, Grimm M, Schneider F, Jedamzik P, Sager M, K\u00fchn JP, et al. Navigating the human gastrointestinal tract for oral drug delivery: uncharted waters and new frontiers. Adv Drug Deliv Rev. 2016;101:75\u201388.","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"601_CR46","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1021\/acs.molpharmaceut.7b00623","volume":"14","author":"M Grimm","year":"2017","unstructured":"Grimm M, Scholz E, Koziolek M, Kuhn JP, Weitschies W. Gastric water emptying under fed state clinical trial conditions is as fast as under fasted conditions. Mol Pharm. 2017;14(12):4262\u201371.","journal-title":"Mol Pharm"},{"issue":"6","key":"601_CR47","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.jbiomech.2006.06.006","volume":"40","author":"A Pal","year":"2007","unstructured":"Pal A, Brasseur JG, Abrahamsson B. A stomach road or \"Magenstrasse\" for gastric emptying. J Biomech. 2007;40(6):1202\u201310.","journal-title":"J Biomech"},{"issue":"7","key":"601_CR48","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","volume":"25","author":"E Jantratid","year":"2008","unstructured":"Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 2008;25(7):1663\u201376.","journal-title":"Pharm Res"},{"key":"601_CR49","unstructured":"Biorelevant.com homepage [Available from: https:\/\/biorelevant.com\/Fed_Gastric_Dissolution_Media\/"},{"issue":"6","key":"601_CR50","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/gut.32.6.615","volume":"32","author":"PJ Collins","year":"1991","unstructured":"Collins PJ, Houghton LA, Read NW, Horowitz M, Chatterton BE, Heddle R, et al. Role of the proximal and distal stomach in mixed solid and liquid meal emptying. Gut. 1991;32(6):615\u20139.","journal-title":"Gut."},{"issue":"2","key":"601_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ejpb.2008.05.011","volume":"70","author":"W Weitschies","year":"2008","unstructured":"Weitschies W, Friedrich C, Wedemeyer RS, Schmidtmann M, Kosch O, Kinzig M, et al. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur J Pharm Biopharm. 2008;70(2):641\u20138.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2-3","key":"601_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jconrel.2005.08.018","volume":"108","author":"W Weitschies","year":"2005","unstructured":"Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Soderlind E, et al. Impact of the intragastric location of extended release tablets on food interactions. J Control Release. 2005;108(2-3):375\u201385.","journal-title":"J Control Release"},{"issue":"1-2","key":"601_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijpharm.2010.04.047","volume":"395","author":"JM Newton","year":"2010","unstructured":"Newton JM. Gastric emptying of multi-particulate dosage forms. Int J Pharm. 2010;395(1-2):2\u20138.","journal-title":"Int J Pharm"},{"issue":"1","key":"601_CR54","doi-asserted-by":"publisher","first-page":"G11","DOI":"10.1152\/ajpgi.00498.2005","volume":"292","author":"O Goetze","year":"2007","unstructured":"Goetze O, Steingoetter A, Menne D, van der Voort IR, Kwiatek MA, Boesiger P, et al. The effect of macronutrients on gastric volume responses and gastric emptying in humans: a magnetic resonance imaging study. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G11\u20137.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"601_CR55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1021\/acs.molpharmaceut.7b00919","volume":"15","author":"M Grimm","year":"2018","unstructured":"Grimm M, Koziolek M, Saleh M, Schneider F, Garbacz G, Kuhn JP, et al. Gastric emptying and small bowel water content after administration of grapefruit juice compared to water and isocaloric solutions of glucose and fructose: a four-way crossover MRI pilot study in healthy subjects. Mol Pharm. 2018;15(2):548\u201359.","journal-title":"Mol Pharm"},{"issue":"12","key":"601_CR56","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1136\/gut.28.12.1584","volume":"28","author":"LA Houghton","year":"1987","unstructured":"Houghton LA, Hickson F, Read NW. Effect of food consistency on gastric emptying in man. Gut. 1987;28(12):1584\u20138.","journal-title":"Gut."},{"issue":"5","key":"601_CR57","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1021\/mp500022u","volume":"11","author":"M Koziolek","year":"2014","unstructured":"Koziolek M, Grimm M, Garbacz G, Kuhn JP, Weitschies W. Intragastric volume changes after intake of a high-caloric, high-fat standard breakfast in healthy human subjects investigated by MRI. Mol Pharm. 2014;11(5):1632\u20139.","journal-title":"Mol Pharm"},{"issue":"7","key":"601_CR58","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/ejcn.2013.78","volume":"67","author":"L Marciani","year":"2013","unstructured":"Marciani L, Pritchard SE, Hellier-Woods C, Costigan C, Hoad CL, Gowland PA, et al. Delayed gastric emptying and reduced postprandial small bowel water content of equicaloric whole meal bread versus rice meals in healthy subjects: novel MRI insights. Eur J Clin Nutr. 2013;67(7):754\u20138.","journal-title":"Eur J Clin Nutr"},{"key":"601_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ejpb.2015.05.015","volume":"94","author":"A Fuchs","year":"2015","unstructured":"Fuchs A, Leigh M, Kloefer B, Dressman JB. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3. Eur J Pharm Biopharm. 2015;94:229\u201340.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"601_CR60","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1021\/mp100144v","volume":"7","author":"E Soderlind","year":"2010","unstructured":"Soderlind E, Karlsson E, Carlsson A, Kong R, Lenz A, Lindborg S, et al. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol Pharm. 2010;7(5):1498\u2013507.","journal-title":"Mol Pharm"},{"issue":"6","key":"601_CR61","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1021\/acs.molpharmaceut.9b00187","volume":"16","author":"J Al-Gousous","year":"2019","unstructured":"Al-Gousous J, Salehi N, Amidon GE, Ziff RM, Langguth P, Amidon GL. Mass transport analysis of bicarbonate buffer: effect of the CO 2 \u2013 H 2 CO 3 hydration\u2013dehydration kinetics in the fluid boundary layer and the apparent effective p K a controlling dissolution of acids and bases. Mol Pharm. 2019;16(6):2626\u201335.","journal-title":"Mol Pharm"},{"key":"601_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2019.06.006","volume":"142","author":"D Amaral Silva","year":"2019","unstructured":"Amaral Silva D, Al-Gousous J, Davies NM, Bou Chacra N, Webster GK, Lipka E, et al. Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer. Eur J Pharm Biopharm. 2019;142:8\u201319.","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"601_CR63","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/jps.24460","volume":"104","author":"BJ Krieg","year":"2015","unstructured":"Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. In vivo predictive dissolution: comparing the effect of bicarbonate and phosphate buffer on the dissolution of weak acids and weak bases. J Pharm Sci. 2015;104(9):2894\u2013904.","journal-title":"J Pharm Sci"},{"key":"601_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejps.2013.09.020","volume":"51","author":"G Garbacz","year":"2014","unstructured":"Garbacz G, Kolodziej B, Koziolek M, Weitschies W, Klein S. A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds. Eur J Pharm Sci. 2014;51:224\u201331.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"601_CR65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1211\/0022357022511","volume":"56","author":"ES Kostewicz","year":"2004","unstructured":"Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004;56(1):43\u201351.","journal-title":"J Pharm Pharmacol"},{"key":"601_CR66","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jphp.12951","volume":"71","author":"PJ O'Dwyer","year":"2019","unstructured":"O'Dwyer PJ, Litou C, Box KJ, Dressman JB, Kostewicz ES, Kuentz M, et al. In vitro methods to assess drug precipitation in the fasted small intestine - a PEARRL review. J Pharm Pharmacol. 2019;71:536\u201356.","journal-title":"J Pharm Pharmacol"},{"issue":"10","key":"601_CR67","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s11095-010-0213-8","volume":"27","author":"S Carlert","year":"2010","unstructured":"Carlert S, Palsson A, Hanisch G, von Corswant C, Nilsson C, Lindfors L, et al. Predicting intestinal precipitation-a case example for a basic BCS class II drug. Pharm Res. 2010;27(10):2119\u201330.","journal-title":"Pharm Res"},{"issue":"12","key":"601_CR68","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1021\/acs.molpharmaceut.7b00198","volume":"14","author":"J Mann","year":"2017","unstructured":"Mann J, Dressman J, Rosenblatt K, Ashworth L, Muenster U, Frank K, et al. Validation of dissolution testing with biorelevant media: an OrBiTo study. Mol Pharm. 2017;14(12):4192\u2013201.","journal-title":"Mol Pharm"},{"key":"601_CR69","unstructured":"FDA. Chemistry review for Votrient (NDA 22-465). 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000_ChemR.pdf"},{"key":"601_CR70","unstructured":"Drugbank. Pazopanib. 2012. p. https:\/\/go.drugbank.com\/drugs\/DB06589"},{"key":"601_CR71","unstructured":"GSK. An open-label, two-part study to characterize the pharmacokinetics of a single intravenous dose of pazopanib (GW786034) and the absorption, distribution, metabolism and elimination of a single oral [14C] labeled dose of pazopanib in subjects with solid tumor malignancies: final report. In: Register G-CS, editor. 2009. https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/VEG10004\/95aab286-8399-4dd6-bd42-48bea4cc216e\/c90d2a8d-138f-4c28-8e5f-d37a5219d5f9\/veg10004-clinical-study-report-redact-v02-v1.pdf"},{"key":"601_CR72","unstructured":"FDA. Chemistry review for Sanctura XR (NDA 22-103). 2007. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022103s000_ChemR.pdf"},{"issue":"12","key":"601_CR73","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1021\/cg4007394","volume":"13","author":"E Sko\u0159epov\u00e1","year":"2013","unstructured":"Sko\u0159epov\u00e1 E, \u010cejka J, Hu\u0161\u00e1k M, Eigner V, Rohl\u00ed\u010dek J, \u0160turc A, et al. Trospium chloride: unusual example of polymorphism based on structure disorder. Cryst Growth Des. 2013;13(12):5193\u2013203.","journal-title":"Cryst Growth Des"},{"issue":"11","key":"601_CR74","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.4155\/bio.14.3","volume":"6","author":"L Mercolini","year":"2014","unstructured":"Mercolini L, Mandrioli R, Protti M, Conca A, Albers L, Raggi M. Dried blood spot testing: a novel approach for the therapeutic drug monitoring of ziprasidone-treated patients. Bioanalysis. 2014;6(11):1487\u201395.","journal-title":"Bioanalysis."},{"issue":"13-14","key":"601_CR75","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jchromb.2010.02.028","volume":"878","author":"KK Hotha","year":"2010","unstructured":"Hotha KK, Bharathi DV, Kumar SS, Reddy YN, Chatki PK, Ravindranath LK, et al. Determination of the quaternary ammonium compound trospium in human plasma by LC-MS\/MS: application to a pharmacokinetic study. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(13-14):981\u20136.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00601-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-021-00601-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-021-00601-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T16:10:44Z","timestamp":1629303044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-021-00601-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1208\/s12248-021-00601-0","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"assertion":[{"value":"30 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"85"}}